{
 "@context": "https://clearank.com/llms.txt",
 "@type": "clearank:AssetAnalysis",
 "url": "https://clearank.com/stock/stryker-syk/",
 "dataUrl": "https://clearank.com/stock/stryker-syk/data.json",
 "title": "Stryker (SYK) Stock Forecast & Price Target (2026)",
 "description": "Stryker Corp. (SYK) stock: Healthcare, Medical Devices. $105.7B market cap. AI rating, technicals, 2030 forecast and trade plans.",
 "headline": "Stryker Corp. (SYK)",
 "published": "2026-07-27T09:34:20+00:00",
 "modified": "2026-09-13T00:26:29.505+00:00",
 "generated": "2026-09-13T02:39:19.128Z",
 "language": "en-US",
 "publisher": {
  "name": "CleaRank",
  "url": "https://clearank.com/"
 },
 "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by the CleaRank editorial team; prices delayed up to 15 minutes.",
 "asset": {
  "ticker": "SYK",
  "name": "Stryker Corp.",
  "type": "Common Stock",
  "exchange": "NYSE",
  "currency": "USD",
  "sector": "Healthcare",
  "industry": "Medical Devices",
  "country": "United States",
  "website": "https://www.stryker.com"
 },
 "quote": {
  "price": 275.56,
  "previousClose": 270.01,
  "change": 5.55,
  "changePercent": 2.06,
  "open": 270.72,
  "high": 277,
  "low": 267,
  "volume": 3723800,
  "averageVolume": 3266830,
  "marketCap": 105697388555,
  "fiftyTwoWeekHigh": 396.85999,
  "fiftyTwoWeekLow": 267,
  "marketOpen": false,
  "asOf": "2026-09-13T00:26:29.000Z"
 },
 "statistics": {
  "pe": 28.58506,
  "eps": 9.64,
  "dividendYield": 0.012778160904641737,
  "beta": 0.768,
  "priceToSales": 4.090931,
  "priceToBook": 4.406281,
  "revenueTtm": 25837000704,
  "grossMargin": 0.6826529063590833,
  "returnOnEquity": 0.16508
 },
 "technicals": {
  "rsi": 19.27,
  "macd": -14.35,
  "sma50": 325.03,
  "sma200": 336.68,
  "rsiSignal": "Oversold",
  "trend": "Bearish",
  "pricePosition": "Bearish",
  "macdSignal": "Bearish",
  "rating": "Bearish"
 },
 "analysis": {
  "rating": "Buy",
  "score": 76,
  "consensus": "Buy",
  "fairValue": 380,
  "analystTarget": 380,
  "analystCount": 28,
  "wallStreetConsensus": "Buy",
  "generatedAt": "2026-09-13T00:26:29.000Z",
  "priceAtAnalysis": 275.56,
  "volatility": {
   "daily": 2.38,
   "risk": "standard"
  }
 },
 "tradePlan": {
  "bias": "Bullish",
  "conservativeEntry": 270.05,
  "aggressiveEntry": 275.56,
  "stopLoss": 253.36,
  "stopLossPercent": 6.18,
  "targets": [
   283.55,
   297.05,
   310.56
  ]
 },
 "projections": {
  "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets",
  "years": [
   {
    "year": 2027,
    "downside10th": 211.21,
    "base": 298.71,
    "upside90th": 422.47
   },
   {
    "year": 2028,
    "downside10th": 198.33,
    "base": 323.81,
    "upside90th": 528.68
   },
   {
    "year": 2029,
    "downside10th": 192.57,
    "base": 351.02,
    "upside90th": 639.85
   },
   {
    "year": 2030,
    "downside10th": 190.23,
    "base": 380.51,
    "upside90th": 761.12
   },
   {
    "year": 2031,
    "downside10th": 190.02,
    "base": 412.48,
    "upside90th": 895.42
   },
   {
    "year": 2032,
    "downside10th": 191.29,
    "base": 447.14,
    "upside90th": 1045.19
   },
   {
    "year": 2033,
    "downside10th": 193.73,
    "base": 484.71,
    "upside90th": 1212.77
   },
   {
    "year": 2034,
    "downside10th": 197.12,
    "base": 525.44,
    "upside90th": 1400.61
   },
   {
    "year": 2035,
    "downside10th": 201.34,
    "base": 569.59,
    "upside90th": 1611.32
   },
   {
    "year": 2036,
    "downside10th": 206.32,
    "base": 617.45,
    "upside90th": 1847.78
   }
  ]
 },
 "faqCount": 7,
 "sources": [
  "TwelveData",
  "Wall Street consensus"
 ],
 "sections": [
  {
   "id": "price",
   "title": "SYK Price Analysis"
  },
  {
   "id": "market-metrics",
   "title": "Market Metrics",
   "facts": {
    "Open": "$270.72",
    "Day Range": "$267.00 to $277.00",
    "Prev Close": "$270.01",
    "Volume": "3.72M",
    "52-Week Range": "$267.00 to $396.86",
    "Market Cap": "$105.70B"
   }
  },
  {
   "id": "peer-benchmarking",
   "title": "Peer Benchmarking",
   "text": [
    "Sector Position Analysis Valuation is broadly in line with sector peers (-10% difference), suggesting fair market pricing relative to industry standards."
   ]
  },
  {
   "id": "financials",
   "title": "SYK Financial Performance",
   "text": [
    "Analysis: In the last 4 quarters, SYK beat estimates 3 times. However, the stock fell 2 times the next day. This suggests positive news is often \"priced in\" or investors are selling the news."
   ]
  },
  {
   "id": "analysis",
   "title": "SYK Analysis",
   "text": [
    "Stryker Corp. (SYK) exhibits significantly oversold technical conditions, with its RSI at 19.27, signaling a potential for a near-term bounce. The stock is trading below its 20-day, 50-day, and 200-day moving averages, with the 50-day SMA at $325.03 and the 200-day SMA at $336.68, indicating a strong downtrend. MACD is also negative at -14.35, reinforcing the bearish momentum. Volume on the latest trading day was 3.72 million, 14% above the average, suggesting increased selling pressure or potential accumulation at lower levels. Key support levels are not clearly defined due to the current trend, but the oversold RSI may offer a temporary floor.",
    "Analyst estimates indicate strong revenue growth of 10.00% for the current quarter and 12.00% for the next quarter, signaling continued market demand for Stryker's products.",
    "The RSI reading of 19.27 suggests the stock is significantly oversold, which historically precedes potential price reversals and could lead to a short-term rally.",
    "Over $738 million in insider sales have been recorded, indicating a potential lack of confidence from management and executives regarding the stock's near-term prospects.",
    "Stryker Corp. is trading significantly below its 50-day and 200-day moving averages ($325.03 and $336.68), confirming a strong bearish trend and suggesting further downside potential.",
    "Stryker Corp. (SYK) is positioned for a potential recovery, with Wall Street analysts projecting a median price target of $380, implying a 37.9% upside from the current $275.56. The company's strong fundamental performance, including strong profit margins and projected revenue growth, supports this optimistic outlook. The current oversold RSI reading of 19.27 suggests that the stock may be due for a technical rebound. The company's forward-looking revenue growth estimates of 10.00% for the current quarter and 12.00% for the next quarter further strengthen the case for a positive trajectory."
   ],
   "lists": {
    "ProTips": [
     "Significant insider selling totaling over $738 million warrants close monitoring for any further negative signals.",
     "The current oversold RSI of 19.27 suggests a potential for a short-term technical bounce, offering a possible entry point for traders.",
     "Given the current bearish technical trend, consider implementing a stop-loss order below key support levels to manage downside risk."
    ]
   },
   "catalysts": [
    {
     "type": "Bullish",
     "title": "Strong Revenue Growth Projections",
     "text": "Analyst estimates indicate strong revenue growth of 10.00% for the current quarter and 12.00% for the next quarter, signaling continued market demand for Stryker's products.",
     "source": "Wall Street Estimates"
    },
    {
     "type": "Bullish",
     "title": "Oversold Technical Conditions",
     "text": "The RSI reading of 19.27 suggests the stock is significantly oversold, which historically precedes potential price reversals and could lead to a short-term rally.",
     "source": "Technical Analysis"
    },
    {
     "type": "Bearish",
     "title": "Heavy Insider Selling Activity",
     "text": "Over $738 million in insider sales have been recorded, indicating a potential lack of confidence from management and executives regarding the stock's near-term prospects.",
     "source": "Insider Transactions"
    },
    {
     "type": "Bearish",
     "title": "Bearish Moving Average Crossovers",
     "text": "Stryker Corp. is trading significantly below its 50-day and 200-day moving averages ($325.03 and $336.68), confirming a strong bearish trend and suggesting further downside potential.",
     "source": "Technical Analysis"
    }
   ]
  },
  {
   "id": "key-statistics",
   "title": "Key Statistics",
   "text": [
    "Stryker Corp. (SYK) trades at a P/E ratio of 28.59, which is slightly below the sector median of 31.9, suggesting a reasonable valuation relative to peers. Its price-to-sales ratio stands at 4.09, compared to the sector median of 3.7, indicating a slight premium. The company boasts a healthy profit margin of 14.43% and an operating margin of 27.02%, outperforming the sector's median ROE of 6.9%. With a debt-to-equity ratio of 0.64, the balance sheet appears manageable. Despite the current price weakness, the company's profitability and efficiency metrics suggest underlying strength.",
    "Stryker Corp. (SYK) recently reported Q2 2026 earnings with an EPS of $3.69, beating the estimate of $3.49 by 5.73%, though the stock reacted negatively with a -6.42% price change. This follows a pattern of mixed earnings performance, with a miss in the prior quarter (-12.75% surprise) and a beat in the quarter before that (+1.59% surprise). Revenue growth is projected to be strong, with an estimated 10.00% increase for the current quarter and 12.00% for the next quarter, indicating continued top-line expansion.",
    "The primary risk for Stryker Corp. (SYK) stems from significant insider selling, with over $738 million in sales reported, indicating potential concerns among management regarding future performance or valuation. Additionally, the stock is trading significantly below its key moving averages, highlighting a strong bearish technical trend that could persist. While the company has a solid financial foundation, the heavy insider selling warrants caution and suggests potential headwinds not fully captured by current analyst targets."
   ],
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "Market Cap",
       "cells": [
        "105.70B"
       ]
      },
      {
       "label": "P/E Ratio",
       "cells": [
        "28.59"
       ]
      },
      {
       "label": "EPS (TTM)",
       "cells": [
        "9.64"
       ]
      },
      {
       "label": "Dividend Yield",
       "cells": [
        "1.26%"
       ]
      },
      {
       "label": "52 Week High",
       "cells": [
        "396.86"
       ]
      },
      {
       "label": "52 Week Low",
       "cells": [
        "267.00"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "technical-indicators",
   "title": "Technical Indicators",
   "text": [
    "Technical Rating Bearish RSI Oversold SMA Cross Bearish Price vs SMA Bearish MACD Bearish Moving averages show a lagging Death Cross (50-day: $325.03, 200-day: $336.68), price is trading below the 50-day SMA, RSI at 19.3 suggests oversold conditions; potential bounce setup."
   ],
   "facts": {
    "RSI": "Oversold",
    "SMA Cross": "Bearish",
    "Price vs SMA": "Bearish",
    "MACD": "Bearish"
   },
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "RSI (14)",
       "cells": [
        "19.27"
       ]
      },
      {
       "label": "MACD",
       "cells": [
        "-14.35"
       ]
      },
      {
       "label": "SMA 50",
       "cells": [
        "325.03"
       ]
      },
      {
       "label": "SMA 200",
       "cells": [
        "336.68"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "correlations",
   "title": "Market Correlations",
   "text": [
    "How this stock moves relative to other assets",
    "Based on 1 year of daily price data. Correlations may vary over different time periods."
   ],
   "facts": {
    "Correlation with S&P 500 (SPY)": "+0.36",
    "Correlation with Nasdaq 100 (QQQ)": "+0.21",
    "Correlation with Bitcoin (BTC)": "-0.17",
    "Correlation with Gold (XAU)": "+0.01"
   }
  },
  {
   "id": "trade-plans",
   "title": "SYK Trade Plans",
   "text": [
    "Specific entry, exit, and risk management levels",
    "Lower risk, wait for pullback",
    "Higher risk, immediate entry",
    "Volatility-Adjusted Stop Loss Calculated based on RSI (19.3) and current market volatility",
    "Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3"
   ],
   "facts": {
    "TARGET 1": "$283.55",
    "TARGET 2": "$297.05",
    "TARGET 3": "$310.56",
    "STOP LOSS": "$253.36"
   }
  },
  {
   "id": "seasonality",
   "title": "Seasonal Patterns",
   "text": [
    "Historical monthly performance trends",
    "Based on 3 years of historical monthly returns"
   ],
   "facts": {
    "Average Jan return": "+3.91%",
    "Average Feb return": "+1.30%",
    "Average Mar return": "-1.98%",
    "Average Apr return": "+2.97%",
    "Average May return": "+1.25%",
    "Average Jun return": "+0.34%",
    "Average Jul return": "+1.30%",
    "Average Aug return": "+1.67%",
    "Average Sep return": "-0.39%",
    "Average Oct return": "+0.09%",
    "Average Nov return": "+3.06%",
    "Average Dec return": "+0.73%"
   }
  },
  {
   "id": "risk",
   "title": "Risk & Volatility",
   "facts": {
    "Daily Volatility": "2.38%"
   },
   "lists": {
    "Risk considerations": [
     "Monitor position sizing based on current volatility levels",
     "Consider stop-loss placement beyond recent price range",
     "Diversification helps mitigate single-stock risk exposure"
    ]
   }
  },
  {
   "id": "growth",
   "title": "Growth of $10,000",
   "text": [
    "A $10,000 investment in SYK in September 2016 would be worth about $24,933 today, compared with about $35,843 for the same investment in the S&P 500 benchmark."
   ]
  },
  {
   "id": "monte-carlo",
   "title": "Monte Carlo Projection (10yr)",
   "text": [
    "CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in SYK today could grow to about $22,407 by 2036 in the base case, with a bull case near $67,056 and a bear case around $7,487. Projections are statistical simulations, not guarantees."
   ]
  },
  {
   "id": "price-prediction",
   "title": "SYK Stock Price Prediction: 2030",
   "text": [
    "CleaRank's simulation projects a price near $381 for SYK by 2030 in the base case, from $276 today (1.4x over 4 years). The downside path ends near $190. These are outcomes of a Monte Carlo simulation run on SYK's historical return distribution, not price targets, and they assume no dividends are reinvested.",
    "Method: 10,000 simulated price paths using SYK's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice."
   ],
   "tables": [
    {
     "caption": "SYK simulated price paths by year",
     "columns": [
      "Year",
      "Downside (10th pct)",
      "Base case",
      "Upside (90th pct)"
     ],
     "rows": [
      {
       "label": "2027",
       "cells": [
        "$211",
        "$299",
        "$422"
       ]
      },
      {
       "label": "2028",
       "cells": [
        "$198",
        "$324",
        "$529"
       ]
      },
      {
       "label": "2029",
       "cells": [
        "$193",
        "$351",
        "$640"
       ]
      },
      {
       "label": "2030",
       "cells": [
        "$190",
        "$381",
        "$761"
       ]
      },
      {
       "label": "2031",
       "cells": [
        "$190",
        "$412",
        "$895"
       ]
      },
      {
       "label": "2032",
       "cells": [
        "$191",
        "$447",
        "$1,045"
       ]
      },
      {
       "label": "2033",
       "cells": [
        "$194",
        "$485",
        "$1,213"
       ]
      },
      {
       "label": "2034",
       "cells": [
        "$197",
        "$525",
        "$1,401"
       ]
      },
      {
       "label": "2035",
       "cells": [
        "$201",
        "$570",
        "$1,611"
       ]
      },
      {
       "label": "2036",
       "cells": [
        "$206",
        "$617",
        "$1,848"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "people-also-watch",
   "title": "People Also Watch",
   "links": [
    {
     "text": "REGN Regeneron Pharmaceuticals, Inc. NASDAQ $781.49 -1.48%",
     "url": "https://clearank.com/stock/regeneron-regn/"
    },
    {
     "text": "HCA HCA Healthcare, Inc. NYSE $426.94 +1.36%",
     "url": "https://clearank.com/stock/hca-healthcare-hca/"
    },
    {
     "text": "NVO Novo Nordisk A/S Sponsored NYSE $43.07 -2.14%",
     "url": "https://clearank.com/stock/novo-nordisk-nvo/"
    },
    {
     "text": "GILD Gilead Sciences, Inc. NASDAQ $143.72 -0.75%",
     "url": "https://clearank.com/stock/gilead-sciences-gild/"
    },
    {
     "text": "GEHC GE HealthCare Technologies Inc. NASDAQ $63.93 -0.48%",
     "url": "https://clearank.com/stock/ge-healthcare-gehc/"
    },
    {
     "text": "ELV Elevance Health, Inc. NYSE $418.72 +0.52%",
     "url": "https://clearank.com/stock/elv-stock-analysis/"
    },
    {
     "text": "TEM Tempus AI Inc NASDAQ $59.02 +0.48%",
     "url": "https://clearank.com/stock/tempus-ai-tem/"
    },
    {
     "text": "VKTX Viking Therapeutics, Inc. NASDAQ $31.98 -0.47%",
     "url": "https://clearank.com/stock/viking-therapeutics-vktx/"
    }
   ]
  },
  {
   "id": "related-comparisons",
   "title": "Popular Comparisons",
   "links": [
    {
     "text": "COST vs WMT Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/cost-vs-wmt/"
    },
    {
     "text": "TSLA vs NVDA Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/tsla-vs-nvda/"
    },
    {
     "text": "VOO vs VOOG Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/voo-vs-voog/"
    }
   ]
  },
  {
   "id": "insider-trading",
   "title": "SYK Insider Trading Analysis",
   "facts": {
    "Bought": "None",
    "Sold": "$738.2M",
    "Insiders": "22",
    "Avg Transaction": "$46.1M"
   },
   "tables": [
    {
     "caption": "Recent insider transactions in SYK",
     "columns": [
      "Date",
      "Insider",
      "Type",
      "Shares",
      "Value"
     ],
     "rows": [
      {
       "label": "Nov 6, 2025",
       "cells": [
        "STRYKER RONDA E Director",
        "Sell",
        "520.0K",
        "$184.6M"
       ]
      },
      {
       "label": "Feb 5, 2026",
       "cells": [
        "STRYKER RONDA E Director",
        "Sell",
        "500.0K",
        "$181.7M"
       ]
      },
      {
       "label": "Feb 7, 2023",
       "cells": [
        "STRYKER RONDA E Director and Beneficial Owner of more than 10% of a Class of Security",
        "Sell",
        "520.0K",
        "$141.9M"
       ]
      },
      {
       "label": "Aug 19, 2026",
       "cells": [
        "STRYKER RONDA E Director",
        "Sell",
        "350.0K",
        "$117.8M"
       ]
      },
      {
       "label": "Feb 6, 2024",
       "cells": [
        "STRYKER RONDA E Director and Beneficial Owner of more than 10% of a Class of Security",
        "Sell",
        "293.4K",
        "$100.3M"
       ]
      },
      {
       "label": "May 26, 2026",
       "cells": [
        "STRYKER RONDA E Director",
        "Sell",
        "310.0K",
        "$96.8M"
       ]
      },
      {
       "label": "Jan 31, 2025",
       "cells": [
        "STRYKER RONDA E Director and Beneficial Owner of more than 10% of a Class of Security",
        "Sell",
        "236.0K",
        "$92.7M"
       ]
      },
      {
       "label": "Nov 5, 2024",
       "cells": [
        "STRYKER RONDA E Director and Beneficial Owner of more than 10% of a Class of Security",
        "Sell",
        "230.0K",
        "$84.5M"
       ]
      },
      {
       "label": "Jan 31, 2025",
       "cells": [
        "STRYKER RONDA E Director and Beneficial Owner of more than 10% of a Class of Security",
        "Sell",
        "201.4K",
        "$79.0M"
       ]
      },
      {
       "label": "May 6, 2025",
       "cells": [
        "STRYKER RONDA E Director and Beneficial Owner of more than 10% of a Class of Security",
        "Sell",
        "200.0K",
        "$75.4M"
       ]
      }
     ]
    }
   ],
   "links": [
    {
     "text": "SEC Form 4",
     "url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&company=Stryker+Corp.&type=4&dateb=&owner=include&count=40&search_text=&action=getcompany"
    }
   ]
  },
  {
   "id": "faq",
   "title": "Frequently Asked Questions"
  }
 ],
 "faq": [
  {
   "question": "Is Stryker Corp. stock a buy right now?",
   "answer": "Stryker Corp. (SYK) is currently rated a 'Buy' by Wall Street analysts, with a median price target of $380, offering a 37.9% upside from its current price of $275.56. The stock exhibits oversold technical conditions, which could precede a rebound, but significant insider selling presents a notable risk."
  },
  {
   "question": "What is Stryker Corp.'s price target for September 2026?",
   "answer": "The median analyst price target for Stryker Corp. (SYK) is $380, with a high of $465 and a low of $315. This target suggests an upside potential of 37.9% from the current price of $275.56."
  },
  {
   "question": "How are Stryker Corp.'s recent earnings?",
   "answer": "Stryker Corp. (SYK) most recently reported Q2 2026 EPS of $3.69, beating estimates by 5.73%, although the stock saw a negative price reaction. The company has a history of mixed earnings surprises but is expected to show strong revenue growth in the upcoming quarters."
  },
  {
   "question": "What is the revenue growth outlook for Stryker Corp.?",
   "answer": "Stryker Corp. (SYK) is projected to achieve revenue growth of 10.00% in the current quarter and 12.00% in the next quarter. For the full year, revenue growth is estimated at 9.00%, with a similar projection for the following year."
  },
  {
   "question": "What are the main risks facing Stryker Corp.?",
   "answer": "The primary risks for Stryker Corp. (SYK) include significant insider selling totaling over $738 million, which may signal management concerns, and a prevailing bearish technical trend with the stock trading well below its key moving averages."
  },
  {
   "question": "How does Stryker Corp. compare to its sector peers?",
   "answer": "Stryker Corp. (SYK) operates in the Healthcare sector with a P/E of 28.59, slightly below the sector median of 31.9, but its price-to-sales ratio of 4.09 is above the sector median of 3.7. The company's profit margin and ROE significantly outperform sector averages."
  },
  {
   "question": "What is Stryker Corp.'s stock forecast for 2030?",
   "answer": "Based on Monte Carlo simulations, Stryker Corp.'s (SYK) stock forecast for 2030 includes a base case price of $380.51, a downside projection of $190.23, and an upside projection of $761.12. These are statistical outcomes, not guaranteed price targets."
  }
 ],
 "related": {
  "peopleAlsoWatch": [
   {
    "ticker": "REGN",
    "name": "Regeneron Pharmaceuticals, Inc. NASDAQ",
    "price": "$781.49",
    "change": "-1.48%",
    "url": "https://clearank.com/stock/regeneron-regn/"
   },
   {
    "ticker": "HCA",
    "name": "HCA Healthcare, Inc. NYSE",
    "price": "$426.94",
    "change": "+1.36%",
    "url": "https://clearank.com/stock/hca-healthcare-hca/"
   },
   {
    "ticker": "NVO",
    "name": "Novo Nordisk A/S Sponsored NYSE",
    "price": "$43.07",
    "change": "-2.14%",
    "url": "https://clearank.com/stock/novo-nordisk-nvo/"
   },
   {
    "ticker": "GILD",
    "name": "Gilead Sciences, Inc. NASDAQ",
    "price": "$143.72",
    "change": "-0.75%",
    "url": "https://clearank.com/stock/gilead-sciences-gild/"
   },
   {
    "ticker": "GEHC",
    "name": "GE HealthCare Technologies Inc. NASDAQ",
    "price": "$63.93",
    "change": "-0.48%",
    "url": "https://clearank.com/stock/ge-healthcare-gehc/"
   },
   {
    "ticker": "ELV",
    "name": "Elevance Health, Inc. NYSE",
    "price": "$418.72",
    "change": "+0.52%",
    "url": "https://clearank.com/stock/elv-stock-analysis/"
   },
   {
    "ticker": "TEM",
    "name": "Tempus AI Inc NASDAQ",
    "price": "$59.02",
    "change": "+0.48%",
    "url": "https://clearank.com/stock/tempus-ai-tem/"
   },
   {
    "ticker": "VKTX",
    "name": "Viking Therapeutics, Inc. NASDAQ",
    "price": "$31.98",
    "change": "-0.47%",
    "url": "https://clearank.com/stock/viking-therapeutics-vktx/"
   }
  ],
  "comparisons": [
   {
    "ticker": "COST vs WMT Comparison",
    "name": "",
    "url": "https://clearank.com/compare/cost-vs-wmt/"
   },
   {
    "ticker": "TSLA vs NVDA Comparison",
    "name": "",
    "url": "https://clearank.com/compare/tsla-vs-nvda/"
   },
   {
    "ticker": "VOO vs VOOG Comparison",
    "name": "",
    "url": "https://clearank.com/compare/voo-vs-voog/"
   }
  ],
  "sectorHub": {
   "text": "Browse all Healthcare →",
   "url": "https://clearank.com/sector/healthcare/"
  },
  "Newly Tracked": [
   {
    "ticker": "ILMN",
    "text": "Illumina Inc.",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   },
   {
    "ticker": "O",
    "text": "Realty Income Corp.",
    "url": "https://clearank.com/stock/o-stock-analysis/"
   },
   {
    "ticker": "SPG",
    "text": "Simon Property Group Inc.",
    "url": "https://clearank.com/stock/spg-stock-analysis/"
   },
   {
    "ticker": "JCI",
    "text": "Johnson Controls International",
    "url": "https://clearank.com/stock/jci-stock-analysis/"
   },
   {
    "ticker": "BLDR",
    "text": "Builders FirstSource Inc.",
    "url": "https://clearank.com/stock/bldr-stock-analysis/"
   }
  ],
  "Top Movers (24h)": [
   {
    "ticker": "RAY/USD",
    "text": "↓ 8.33%",
    "url": "https://clearank.com/crypto/raydium-ray-usd/"
   },
   {
    "ticker": "LEU",
    "text": "↓ 8.18%",
    "url": "https://clearank.com/stock/centrus-energy-leu/"
   },
   {
    "ticker": "SYNA",
    "text": "↑ 8.09%",
    "url": "https://clearank.com/stock/synaptics-syna/"
   },
   {
    "ticker": "SMR",
    "text": "↓ 15.67%",
    "url": "https://clearank.com/stock/nuscale-power-smr/"
   },
   {
    "ticker": "XHLD",
    "text": "↑ 15.59%",
    "url": "https://clearank.com/stock/xhld-stock-analysis/"
   }
  ],
  "Also in Healthcare": [
   {
    "ticker": "GEHC",
    "text": "GE HealthCare",
    "url": "https://clearank.com/stock/ge-healthcare-gehc/"
   },
   {
    "ticker": "MDT",
    "text": "Medtronic plc",
    "url": "https://clearank.com/stock/medtronic-mdt/"
   },
   {
    "ticker": "NEOG",
    "text": "Neogen Corporation",
    "url": "https://clearank.com/stock/neogen-neog/"
   },
   {
    "ticker": "OFIX",
    "text": "Orthofix Medical",
    "url": "https://clearank.com/stock/ofix-stock-analysis/"
   },
   {
    "ticker": "QDEL",
    "text": "QuidelOrtho Corporation",
    "url": "https://clearank.com/stock/quidelortho-qdel/"
   }
  ]
 },
 "schema": [
  {
   "@context": "https://schema.org",
   "@graph": [
    {
     "@type": "Place",
     "@id": "https://clearank.com/#place",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/#organization",
     "name": "CleaRank",
     "url": "https://clearank.com",
     "sameAs": [
      "https://twitter.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank"
     ],
     "email": "info@clearank.com",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     },
     "logo": {
      "@type": "ImageObject",
      "@id": "https://clearank.com/#logo",
      "url": "https://clearank.com/wp-content/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "contentUrl": "https://clearank.com/wp-content/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "caption": "CleaRank",
      "inLanguage": "en-US",
      "width": "336",
      "height": "153"
     },
     "description": "The CleaRank vision is to bring clarity to the online trading industry and protect trader interests. We use our proprietary technology, expert analysis and verified trader insights, to deliver data driven broker evaluations you can trust. Our CLEAR™ Score is our foundation, a transparent, unbiased methodology that assesses brokers and firms based on the most critical factors including regulation, fees, platform reliability, and real user experiences. We are here to change an unfair system and unlike other review sites that are influenced by partnerships or subjective opinions, CleaRank is 100% independent–abiding by our rigorous CLEAR™ editorial code. We do not accept financial incentives from brokers, so what you see is what you get with no hidden agendas, just honest, actionable feedback. Clear data. Honest reviews. That's the CleaRank promise",
     "numberOfEmployees": {
      "@type": "QuantitativeValue",
      "value": "40"
     },
     "location": {
      "@id": "https://clearank.com/#place"
     }
    },
    {
     "@type": "WebSite",
     "@id": "https://clearank.com/#website",
     "url": "https://clearank.com",
     "name": "CleaRank",
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "inLanguage": "en-US"
    },
    {
     "@type": "ImageObject",
     "@id": "https://clearank.com/wp-content/uploads/2026/07/SYK-stryker-analysis-2026-07.png",
     "url": "https://clearank.com/wp-content/uploads/2026/07/SYK-stryker-analysis-2026-07.png",
     "width": "1280",
     "height": "720",
     "caption": "Stryker Corporation (SYK) stock price analysis chart for July 2026",
     "inLanguage": "en-US"
    },
    {
     "@type": "BreadcrumbList",
     "@id": "https://clearank.com/stock/stryker-syk/#breadcrumb",
     "itemListElement": [
      {
       "@type": "ListItem",
       "position": "1",
       "item": {
        "@id": "https://clearank.com",
        "name": "Home"
       }
      },
      {
       "@type": "ListItem",
       "position": "2",
       "item": {
        "@id": "https://clearank.com/stock/stryker-syk/",
        "name": "Stryker Corporation (SYK) Stock Analysis"
       }
      }
     ]
    },
    {
     "@type": "WebPage",
     "@id": "https://clearank.com/stock/stryker-syk/#webpage",
     "url": "https://clearank.com/stock/stryker-syk/",
     "name": "Stryker (SYK) Stock Forecast & Price Target (2026)",
     "datePublished": "2026-07-27T09:34:20+00:00",
     "dateModified": "2026-09-13T00:26:29+00:00",
     "isPartOf": {
      "@id": "https://clearank.com/#website"
     },
     "primaryImageOfPage": {
      "@id": "https://clearank.com/wp-content/uploads/2026/07/SYK-stryker-analysis-2026-07.png"
     },
     "inLanguage": "en-US",
     "breadcrumb": {
      "@id": "https://clearank.com/stock/stryker-syk/#breadcrumb"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/writer/clearank/",
     "name": "CleaRank",
     "description": "CleaRank's vision is to bring clarity to the online trading industry and protecting trader interests by delivering data-driven broker evaluations you can trust.",
     "url": "https://clearank.com/writer/clearank/",
     "image": {
      "@type": "ImageObject",
      "@id": "https://secure.gravatar.com/avatar/4900cf75f960a22a21f1c864e98abc4d5285fa159ea1025d0e8a9db5136e28ef?s=96&d=mm&r=g",
      "url": "https://secure.gravatar.com/avatar/4900cf75f960a22a21f1c864e98abc4d5285fa159ea1025d0e8a9db5136e28ef?s=96&d=mm&r=g",
      "caption": "CleaRank",
      "inLanguage": "en-US"
     },
     "sameAs": [
      "https://clearank.com/",
      "https://twitter.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank"
     ],
     "worksFor": {
      "@id": "https://clearank.com/#organization"
     },
     "logo": "https://clearank.com/wp-content/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg"
    },
    {
     "@type": "Article",
     "headline": "Stryker (SYK) Stock Forecast & Price Target (2026)",
     "datePublished": "2026-07-27T09:34:20+00:00",
     "dateModified": "2026-09-13T00:26:29+00:00",
     "author": {
      "@id": "https://clearank.com/writer/clearank/",
      "name": "CleaRank"
     },
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "description": "Stryker Corp. (SYK) stock: Healthcare, Medical Devices. $105.7B market cap. AI rating, technicals, 2030 forecast and trade plans.",
     "name": "Stryker (SYK) Stock Forecast & Price Target (2026)",
     "@id": "https://clearank.com/stock/stryker-syk/#richSnippet",
     "isPartOf": {
      "@id": "https://clearank.com/stock/stryker-syk/#webpage"
     },
     "image": {
      "@id": "https://clearank.com/wp-content/uploads/2026/07/SYK-stryker-analysis-2026-07.png"
     },
     "inLanguage": "en-US",
     "mainEntityOfPage": {
      "@id": "https://clearank.com/stock/stryker-syk/#webpage"
     }
    }
   ]
  },
  {
   "@context": "https://schema.org",
   "@type": "FinancialProduct",
   "name": "Stryker Corp. (SYK)",
   "tickerSymbol": "SYK",
   "url": "https://clearank.com/stock/stryker-syk/",
   "description": "AI-powered financial analysis for Stryker Corp. (SYK) including technical indicators, market metrics, valuation, and price targets - refreshed daily by CleaRank Financial AI.",
   "exchange": "NYSE",
   "offers": {
    "@type": "Offer",
    "price": 275.56,
    "priceCurrency": "USD",
    "availability": "https://schema.org/InStock",
    "url": "https://clearank.com/stock/stryker-syk/",
    "priceValidUntil": "2026-09-14"
   }
  },
  {
   "@context": "https://schema.org",
   "@type": "FAQPage",
   "mainEntity": [
    {
     "@type": "Question",
     "name": "Is Stryker Corp. stock a buy right now?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Stryker Corp. (SYK) is currently rated a 'Buy' by Wall Street analysts, with a median price target of $380, offering a 37.9% upside from its current price of $275.56. The stock exhibits oversold technical conditions, which could precede a rebound, but significant insider selling presents a notable risk."
     }
    },
    {
     "@type": "Question",
     "name": "What is Stryker Corp.'s price target for September 2026?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The median analyst price target for Stryker Corp. (SYK) is $380, with a high of $465 and a low of $315. This target suggests an upside potential of 37.9% from the current price of $275.56."
     }
    },
    {
     "@type": "Question",
     "name": "How are Stryker Corp.'s recent earnings?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Stryker Corp. (SYK) most recently reported Q2 2026 EPS of $3.69, beating estimates by 5.73%, although the stock saw a negative price reaction. The company has a history of mixed earnings surprises but is expected to show strong revenue growth in the upcoming quarters."
     }
    },
    {
     "@type": "Question",
     "name": "What is the revenue growth outlook for Stryker Corp.?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Stryker Corp. (SYK) is projected to achieve revenue growth of 10.00% in the current quarter and 12.00% in the next quarter. For the full year, revenue growth is estimated at 9.00%, with a similar projection for the following year."
     }
    },
    {
     "@type": "Question",
     "name": "What are the main risks facing Stryker Corp.?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The primary risks for Stryker Corp. (SYK) include significant insider selling totaling over $738 million, which may signal management concerns, and a prevailing bearish technical trend with the stock trading well below its key moving averages."
     }
    },
    {
     "@type": "Question",
     "name": "How does Stryker Corp. compare to its sector peers?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Stryker Corp. (SYK) operates in the Healthcare sector with a P/E of 28.59, slightly below the sector median of 31.9, but its price-to-sales ratio of 4.09 is above the sector median of 3.7. The company's profit margin and ROE significantly outperform sector averages."
     }
    },
    {
     "@type": "Question",
     "name": "What is Stryker Corp.'s stock forecast for 2030?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Based on Monte Carlo simulations, Stryker Corp.'s (SYK) stock forecast for 2030 includes a base case price of $380.51, a downside projection of $190.23, and an upside projection of $761.12. These are statistical outcomes, not guaranteed price targets."
     }
    }
   ]
  }
 ]
}